摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

对苯硫基苯甲醇 | 6317-56-2

中文名称
对苯硫基苯甲醇
中文别名
4-苯巯基苯甲醇;芬替康唑中间体;4-苯硫基苯甲醇;4-苯硫基氯苄;4-羟甲基苯硫醚
英文名称
4-hydroxymethylphenyl phenyl sulfide
英文别名
(4-(phenylthio)phenyl)methanol;4-phenylmercaptobenzyl alcohol;4-phenylthiobenzyl alcohol;4-phenylsulfanyl-benzyl alcohol;4-Phenylmercapto-benzylalkohol;p-(phenylthio)benzyl alcohol;(4-phenylsulfanylphenyl)methanol
对苯硫基苯甲醇化学式
CAS
6317-56-2
化学式
C13H12OS
mdl
MFCD04108413
分子量
216.304
InChiKey
PGOAWMRWDZJQTB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    46-48°C
  • 沸点:
    390.2±25.0 °C(Predicted)
  • 密度:
    1.21±0.1 g/cm3(Predicted)
  • 溶解度:
    可溶于DMSO(少许)、甲醇(少许)

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    15
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.076
  • 拓扑面积:
    45.5
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2930909090
  • 危险性防范说明:
    P280,P305+P351+P338
  • 危险性描述:
    H302
  • 储存条件:
    -20°C

SDS

SDS:f5f7398a84c8774851dc22eeebc8432a
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    对苯硫基苯甲醇盐酸 、 sodium hydride 作用下, 以 Petroleum ether 为溶剂, 反应 29.0h, 生成 芬替康唑
    参考文献:
    名称:
    Nardi; Cappelletti; Catto, Arzneimittel-Forschung/Drug Research, 1982, vol. 31, # 12, p. 2123 - 2126
    摘要:
    DOI:
  • 作为产物:
    描述:
    4-苯硫基苯甲醛 在 sodium tetrahydroborate 作用下, 以 甲醇 为溶剂, 反应 1.0h, 以100%的产率得到对苯硫基苯甲醇
    参考文献:
    名称:
    含磺酰基的芳基烷基胺与人5-HT6 5-羟色胺受体的结合。
    摘要:
    各种含磺酰基的化合物(例如磺酰胺,砜)在人5-HT6血清素受体上结合,但是很难确定这种试剂的结合方式之间的关系,即使许多试剂具有共同的SO2部分,也很难鉴定出它们的结合方式。常见的药效团模型。基于这样的假设,麦角灵型构象对于某些含磺酰胺的芳基烷基胺的结合可能很重要,我们准备在h5-HT6受体上检测一系列化合物,包括苯乙胺6,吡咯并乙胺7和苯基哌嗪9。结果(Ki值范围从大约1 nM到> 1000 nM)表明这些试剂中的许多可能以相关方式结合,结构亲和性和结构亲和性研究表明,苯乙胺和苯基哌嗪类似物的苯磺酰胺部分可以被“逆转”,缩写为砜,并移动到相邻位置,而对亲和性的影响相对较小。尽管苯磺酰胺(或相关的芳基磺酰胺)基团可能是各种5-HT6配体所共有的,但即使在相同的芳基烷基胺结构框架内,磺酰胺基团的具体组成和位置也似乎有一定的余地。提出了一种药效团模型来解释当前的一些发现。即使在相同的芳基烷基胺
    DOI:
    10.1021/jm060469q
点击查看最新优质反应信息

文献信息

  • Highly active bidentate N-heterocyclic carbene/ruthenium complexes performing dehydrogenative coupling of alcohols and hydroxides in open air
    作者:Zhi-Qin Wang、Xiao-Sheng Tang、Zhao-Qi Yang、Bao-Yi Yu、Hua-Jing Wang、Wei Sang、Ye Yuan、Cheng Chen、Francis Verpoort
    DOI:10.1039/c9cc03519b
    日期:——
    Eight bidentate NHC/Ru complexes, namely [Ru]-1–[Ru]-8, were designed and prepared. In particular, [Ru]-2 displayed extraordinary performance even in open air for the dehydrogenative coupling of alcohols and hydroxides. Notably, an unprecedentedly low catalyst loading of 250 ppm and the highest TON of 32 800 and TOF of 3200 until now were obtained.
    设计并制备了八种双齿NHC / Ru络合物,即[Ru] -1– [Ru] -8。尤其是,Ru-2在醇和氢氧化物的脱氢偶联中甚至在露天中也表现出非凡的性能。值得注意的是,迄今为止获得了前所未有的低催化剂负载量250 ppm和最高TON 32800和TOF 3200。
  • A General, Efficient, and Functional-Group-Tolerant Catalyst System for the Palladium-Catalyzed Thioetherification of Aryl Bromides and Iodides
    作者:Manuel A. Fernández-Rodríguez、John F. Hartwig
    DOI:10.1021/jo802594d
    日期:2009.2.20
    reaction of aryl bromides and iodides with aliphatic and aromatic thiols catalyzed by palladium complexes of the bisphosphine ligand CyPF-tBu (1) is reported. Reactions occur in excellent yields, broad scope, high tolerance of functional groups, and with turnover numbers that exceed those of previous catalysts by 2 or 3 orders of magnitude. These couplings of bromo- and iodoarenes are more efficient than
    报道了由双膦配体 CyPF- t Bu ( 1 )的钯配合物催化的芳基溴化物和碘化物与脂肪族和芳香族硫醇的交叉偶联反应。反应以优异的产率、广泛的范围、高的官能团耐受性以及比以前催化剂高出 2 或 3 个数量级的周转数发生。这些溴代芳烃和碘代芳烃的偶联比氯芳烃的相应反应更有效,并且可以在较少的催化剂负载和/或更温和的反应条件下进行。因此,以前在芳基氯偶联中报道的范围和官能团耐受性的限制现在得到了克服。
  • Pyrimidine derivatives, method of manufacturing the same, and androgen
    申请人:Otsuka Pharmaceutical Co., Ltd.
    公开号:US05420128A1
    公开(公告)日:1995-05-30
    The invention discloses a pyrimidien derivative expressed in Formula [I]: ##STR1## where R.sup.1 denotes a hydrogen atom or hydroxyl group, R.sup.2 denotes a hydrogen atom, lower alkoxycarbonyl group, lower alkoxy group, halogen atom, lower alkyl group, cycloalkyl group with 3 to 8 carbon atoms, lower alkoxycarbonyl lower alkyl group, carboxyl group, carboxy lower alkyl group, group: --CONHR.sup.6 (R.sup.6 represents a hydrogen atom, a phenyl group, which may possess halogen atom, or lower alkyl group), cyano group, phenyl group which may possess a group selected from the group consisting of hydroxyl group, halogen atom, lower alkyl group, lower alkoxy group and phenylthio group as a substituent, phenyl lower alkyl group which may possess a group selected from the group consisting of hydroxyl group and lower alkoxy group as a substituent on a phenyl ring, lower alkanoyloxy lower alkyl group, benzoyl group, lower alkanoyl group which may possess a halogen atom, or hydroxy lower alkyl group which may possess a group selected from the group consisting of phenyl group and halogen atom as a substituent, R.sup.3 denotes a hydrogen atom, hydroxyl group, lower alkyl group, cycloalkyl group with 3 to 8 carbon atoms, halogen lower alkyl group, or phenyl group, R.sup.4 denotes a hydrogen atom, lower alkyl group, or lower alkoxy group, and R.sup.5 denotes a hydrogen atom, lower alkyl group, lower alkoxy lower alkyl group, or halogen lower alkyl group; provided that R.sup.2 and R.sup.3 may be bonded to each other to form a lower alkylene group with 3 to 5 carbon atoms, or its pharmaceutically available salt. This derivative is excellent in therapeutic effects of benign prostatic hypertrophy, prostatic carcinoma, female hairiness, male baldness or pimple as an androgen inhibitor.
    该发明揭示了一个在式[I]中表示的嘧啶衍生物:其中R.sup.1表示氢原子或羟基,R.sup.2表示氢原子、低烷氧羰基基团、低烷氧基、卤原子、低烷基、具有3至8个碳原子的环烷基、低烷氧羰基低烷基、羧基、羧基低烷基、基团:--CONHR.sup.6(R.sup.6代表氢原子、苯基,可能带有卤原子,或低烷基),氰基、苯基,可能带有羟基、卤原子、低烷基、低烷氧基和苯硫基等取代基的基团,苯基低烷基基团,可能在苯环上带有羟基和低烷氧基等取代基的基团,低烷酰氧基低烷基基团,苯甲酰基、低烷酰基,可能带有卤原子,或羟基低烷基基团,可能带有苯基和卤原子等取代基的基团,R.sup.3表示氢原子、羟基、低烷基、具有3至8个碳原子的环烷基、卤基低烷基,或苯基,R.sup.4表示氢原子、低烷基,或低烷氧基,R.sup.5表示氢原子、低烷基,低烷氧低烷基,或卤基低烷基;条件是R.sup.2和R.sup.3可以连接在一起形成具有3至5个碳原子的低烷基,或其药用可用盐。该衍生物在治疗良性前列腺肥大、前列腺癌、女性多毛症、男性秃发或痤疮等方面作为雄激素抑制剂具有出色的疗效。
  • [EN] GLYOXALASE INHIBITORS<br/>[FR] INHIBITEURS DE LA GLYOXALASE
    申请人:CHROMA THERAPEUTICS LTD
    公开号:WO2004101506A1
    公开(公告)日:2004-11-25
    This invention relates to compounds of formula (I) which are glyoxalase I inhibitors, pharmaceutical salts or compositions comprising such compounds, and the use of such compositions and compounds to treat various conditions alleviated by the inhibition of glyoxalase I. Wherein X is N or CH. R2 is H, CF3; or optionally substituted C5-6 aryl, C3-7 cycloalkyl, C5-7 heterocyclyl. R3 is H; or optionally substituted C5-6 aryl, C3-7 cycloalkyl, C5-7 heterocyclyl. Alternatively R2 and R3 together form an optionally substituted C3-4 alkylene group wherein L3 and L4 are single bonds thus forming a C5-6 ring fused with the aromatic ring to which L3 and L4 are attached. L3 and L4 are independently selected from a single bond, optionally substituted C1-4 alkylene, -L9YN(OH)C(=O)L10- and -L9C(=O)N(OH)YL10-, wherein L9 and L10 are independently selected from optionally substituted C1-4 alkylene, C5-6 arylene, C1-4 alkylene-C5-6 arylene and a single bond, wherein Y is NH or a single bond.
    本发明涉及式(I)化合物,其为乙二醛酶I抑制剂,包括此类化合物的药物盐或组合物,以及使用这些组合物和化合物治疗通过抑制乙二醛酶I缓解的各种病症。其中X为N或CH。R2为H、CF3;或者是可选择的取代C5-6芳基、C3-7环烷基、C5-7杂环基。R3为H;或者是可选择的取代C5-6芳基、C3-7环烷基、C5-7杂环基。或者R2和R3一起形成一个可选择的取代C3-4烷基,其中L3和L4是单键,从而形成一个与L3和L4连接的芳环并嵌合在一起。L3和L4是独立选择的单键、可选择的取代C1-4烷基、-L9YN(OH)C(=O)L10-和-L9C(=O)N(OH)YL10-,其中L9和L10是独立选择的可选择的取代C1-4烷基、C5-6芳基、C1-4烷基-C5-6芳基和单键,其中Y为NH或单键。
  • Characterization of novel sulfonium photoacid generators and their microwave-assisted synthesis
    作者:Ciceron O. Yanez、Carolina D. Andrade、Kevin D. Belfield
    DOI:10.1039/b815831b
    日期:——
    Microwave-assisted synthesis of triarylsulfonium salt photoacid generators (PAGs) afforded reaction times 90 to 420 times faster than conventional thermal conditions, with photoacid quantum yields of new sulfonium PAGs ranging from 0.01 to 0.4.
    微波辅助合成三芳基锍盐光酸发生器(PAGs)的反应时间比传统热条件快 90 至 420 倍,新型锍 PAGs 的光量子产率为 0.01 至 0.4。
查看更多